AEBP1
AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
Overview
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Vemurafenib.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 1 · What it is
AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.
- 2 · What goes wrong in cancer
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix.
- 3 · How drugs use it
No product in this corpus aims at AEBP1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:303 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q8IUX7 (protein name, function text, keywords and locations (REST API)); CIViC gene AEBP1 (1 evidence items, 0 assertions, 1 variants; diseases: Skin Melanoma (GraphQL API, CC0))
Biology
As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor. Location: Secreted; Cytoplasm; Nucleus (UniProt). Locus 7p13 (HGNC).
- Melanoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"AEBP1" OR ABSTRACT:"AEBP1" OR TITLE:"AE binding protein 1" OR ABSTRACT:"AE binding protein 1" OR TITLE:"Adipocyte enhancer-binding protein 1" OR ABSTRACT:"Adipocyte enhancer-binding protein 1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AEBP1, not a curated reading list.